Los Angeles Capital Management LLC Makes New $431,000 Investment in Avantor, Inc. (NYSE:AVTR)

Los Angeles Capital Management LLC purchased a new position in shares of Avantor, Inc. (NYSE:AVTR) in the third quarter, according to its most recent filing with the SEC. The firm purchased 16,645 shares of the company’s stock, valued at approximately $431,000.

Other large investors have also recently bought and sold shares of the company. Versant Capital Management Inc lifted its position in shares of Avantor by 2,003.6% during the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock worth $25,000 after buying an additional 1,102 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Avantor by 1,830.3% during the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after buying an additional 1,391 shares in the last quarter. UMB Bank n.a. bought a new position in shares of Avantor during the 3rd quarter worth approximately $49,000. Nisa Investment Advisors LLC lifted its position in shares of Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after buying an additional 835 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Avantor by 89.9% during the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after buying an additional 1,285 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on AVTR shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $34.00 price target on shares of Avantor in a report on Thursday, September 26th. UBS Group reduced their price objective on shares of Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, October 8th. TD Cowen lifted their price objective on shares of Avantor from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, July 29th. Stifel Nicolaus lifted their price objective on shares of Avantor from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Monday, July 29th. Finally, Robert W. Baird reduced their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, Avantor currently has a consensus rating of “Moderate Buy” and an average price target of $27.57.

Insiders Place Their Bets

In other news, CAO Steven W. Eck sold 3,525 shares of the stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total value of $88,336.50. Following the completion of the sale, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at $740,372.64. This represents a 10.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.50% of the company’s stock.

Avantor Stock Down 1.9 %

Shares of Avantor stock opened at $20.74 on Monday. The company has a market cap of $14.12 billion, a price-to-earnings ratio of 45.09, a price-to-earnings-growth ratio of 2.51 and a beta of 1.35. The company’s 50 day moving average is $24.52 and its 200 day moving average is $24.00. Avantor, Inc. has a twelve month low of $19.11 and a twelve month high of $28.00. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.